國立虎尾科技大學 |

The Politics of Pharmaceutical Policy Reform = A Study of Generic Drug Regulation in Brazil /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	The Politics of Pharmaceutical Policy Reform/ by Elize Massard da Fonseca.
其他題名:	A Study of Generic Drug Regulation in Brazil /
作者:	Massard da Fonseca, Elize.
面頁冊數:	XII, 117 p. 1 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Social policy. -
電子資源:	https://doi.org/10.1007/978-3-319-12565-7
ISBN:	9783319125657

The Politics of Pharmaceutical Policy Reform = A Study of Generic Drug Regulation in Brazil /
Massard da Fonseca, Elize.

The Politics of Pharmaceutical Policy ReformA Study of Generic Drug Regulation in Brazil /[electronic resource] :by Elize Massard da Fonseca. - 1st ed. 2015. - XII, 117 p. 1 illus. in color.online resource. - SpringerBriefs in Political Science,262191-5466 ;. - SpringerBriefs in Political Science,.

Introduction -- Contextualising drug regulation -- The generic drug reform in Brazil -- Assessing the generic drug regulatory process in the 2000s: governmental intervention, market demand and local pharmaceutical industries -- Public production of medicines and HIV/AIDS activists: new actors in the generic drug regulatory process -- Conclusion -- Postscript -- Index -- References -- Annex - Notes on research methodology.

Brazil is renowned worldwide for its remarkable reforms in pharmaceutical regulation, which have enhanced access to essential medicines while lowering drug costs. This book innovates by analysing the generic drug reform in Brazil, demonstrating that pharmaceutical regulation is only partially influenced by non-state actors. Little is known about the institutional antecedents and policy process that channeled this regulatory reform. This is particularly intriguing because a regulatory shift in the pharmaceutical sector requires the participation of a number of stakeholders and interest groups in the policy process. Fonseca examines the generic drug reform’s causes and consequences. No study has approached the generic drug regulation in Brazil from this perspective. The Politics of Pharmaceutical Policy Reform: A Study of Generic Drug Regulation in Brazil, explores the following: · The politics of pharmaceutical regulation in Brazil over the last 25 years. · The political negotiations to approve the Generic Drug Act, which involved a hard-to-reach agreement between the pharmaceutical industry (national and multinational), the Ministry of Health, and Congress · The controversial decisions to regulate packaging and pharmaceutical equivalence. · The surprising success of Brazilian pharmaceutical firms, which became market champions in a sector largely dominated by multinational firms. · Comparative lessons from the Brazilian case for the political construction of regulatory standards to regulate generic drugs and its effects on global health. This book will interest political scientists and health policy scholars concerned with the political conflicts in the pharmaceutical sector. It argues against well-established approaches to regulatory capture such as control of the regulatory process by interest groups and policy diffusion. It can be used as evidence for graduate courses in public policy, health policy and political science. Because Brazil is one of the largest markets for pharmaceuticals in the world, business leaders and consultancy firms would also be interested.

ISBN: 9783319125657

Standard No.: 10.1007/978-3-319-12565-7doiSubjects--Topical Terms:

555261
Social policy.

LC Class. No.: JF20-2112

Dewey Class. No.: 361

The Politics of Pharmaceutical Policy Reform = A Study of Generic Drug Regulation in Brazil /
LDR:04061nam a22004095i 4500 001 966692
003 DE-He213
005 20200920100907.0
007 cr nn 008mamaa
008 201211s2015 gw | s |||| 0|eng d
020 $a 9783319125657 $9 978-3-319-12565-7
024 7 $a 10.1007/978-3-319-12565-7 $2 doi
035 $a 978-3-319-12565-7
050 4 $a JF20-2112
072 7 $a KCP $2 bicssc
072 7 $a POL029000 $2 bisacsh
072 7 $a KCP $2 thema
072 7 $a JBF $2 thema
082 0 4 $a 361 $2 23
100 1 $a Massard da Fonseca, Elize. $e author. $4 aut $4 http://id.loc.gov/vocabulary/relators/aut $3 1262318
245 1 4 $a The Politics of Pharmaceutical Policy Reform $h [electronic resource] : $b A Study of Generic Drug Regulation in Brazil / $c by Elize Massard da Fonseca.
250 $a 1st ed. 2015.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2015.
300 $a XII, 117 p. 1 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a SpringerBriefs in Political Science, $x 2191-5466 ; $v 26
505 0 $a Introduction -- Contextualising drug regulation -- The generic drug reform in Brazil -- Assessing the generic drug regulatory process in the 2000s: governmental intervention, market demand and local pharmaceutical industries -- Public production of medicines and HIV/AIDS activists: new actors in the generic drug regulatory process -- Conclusion -- Postscript -- Index -- References -- Annex - Notes on research methodology.
520 $a Brazil is renowned worldwide for its remarkable reforms in pharmaceutical regulation, which have enhanced access to essential medicines while lowering drug costs. This book innovates by analysing the generic drug reform in Brazil, demonstrating that pharmaceutical regulation is only partially influenced by non-state actors. Little is known about the institutional antecedents and policy process that channeled this regulatory reform. This is particularly intriguing because a regulatory shift in the pharmaceutical sector requires the participation of a number of stakeholders and interest groups in the policy process. Fonseca examines the generic drug reform’s causes and consequences. No study has approached the generic drug regulation in Brazil from this perspective. The Politics of Pharmaceutical Policy Reform: A Study of Generic Drug Regulation in Brazil, explores the following: · The politics of pharmaceutical regulation in Brazil over the last 25 years. · The political negotiations to approve the Generic Drug Act, which involved a hard-to-reach agreement between the pharmaceutical industry (national and multinational), the Ministry of Health, and Congress · The controversial decisions to regulate packaging and pharmaceutical equivalence. · The surprising success of Brazilian pharmaceutical firms, which became market champions in a sector largely dominated by multinational firms. · Comparative lessons from the Brazilian case for the political construction of regulatory standards to regulate generic drugs and its effects on global health. This book will interest political scientists and health policy scholars concerned with the political conflicts in the pharmaceutical sector. It argues against well-established approaches to regulatory capture such as control of the regulatory process by interest groups and policy diffusion. It can be used as evidence for graduate courses in public policy, health policy and political science. Because Brazil is one of the largest markets for pharmaceuticals in the world, business leaders and consultancy firms would also be interested.
650 0 $a Social policy. $3 555261
650 0 $a Economic policy. $3 555567
650 0 $a Political economy. $2 bicssc $3 809016
650 1 4 $a Social Policy. $3 669212
650 2 4 $a Economic Policy. $3 669185
650 2 4 $a International Political Economy. $3 1171863
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319125664
776 0 8 $i Printed edition: $z 9783319125640
830 0 $a SpringerBriefs in Political Science, $x 2191-5466 $3 1256912
856 4 0 $u https://doi.org/10.1007/978-3-319-12565-7
912 $a ZDB-2-SBE
912 $a ZDB-2-SXEF
950 $a Business and Economics (SpringerNature-11643)
950 $a Economics and Finance (R0) (SpringerNature-43720)